Company intelligence / Profile preview

Actuate Health

Fort Worth, Texas, United Statesactuatehealth.com.au ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Actuate’s lead candidate, elraglusib, is a novel GSK‑3 inhibitor in Phase 2 for metastatic pancreatic cancer and earlier-stage trials for refractory Ewing sarcoma and other solid tumors. Early clinical data show activity in multiple hard-to-treat cancers with a focus on overcoming chemoresistance and modulating anti-tumor immunity. The company has received key regulatory designations such as Fast Track and Orphan Drug status for its programs[1][4].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

none disclosed as of June2025

Beyond the preview

Go deeper on Actuate Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actuate Health.

Explore the full profile